Drug Profile
Research programme: interleukin 1-based vaccine (Immuneresuzumab) - Immune Response BioPharma
Alternative Names: Cardiology anti-cholesterol drug IL-1 beta candidate - Immune Response BioPharma; Diabetes vaccine IL-1 beta candidate - Immune Response BioPharma; DiabetesVax; Gout vaccine IL-1 beta candidate - Immune Response BioPharma; GoutVax; HeartVax; Immuneresuzumab; IR-1000; IR-1002; IR-888Latest Information Update: 28 Jan 2018
Price :
$50
*
At a glance
- Originator Immune Response BioPharma
- Class Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cardiovascular disorders; Diabetes mellitus; Gout
Most Recent Events
- 28 Jan 2018 No recent reports of development identified for preclinical development in Cardiovascular-disorders in USA (Parenteral)
- 28 Jan 2018 No recent reports of development identified for preclinical development in Diabetes-mellitus in USA (Parenteral)
- 28 Jan 2018 No recent reports of development identified for preclinical development in Gout in USA (Parenteral)